311 related articles for article (PubMed ID: 31699450)
41. Expanded table: some biologic agents and JAK inhibitors for RA.
Med Lett Drugs Ther; 2018 Jul; 60(1552):e130-e134. PubMed ID: 30044768
[No Abstract] [Full Text] [Related]
42. SOCS-JAK-STAT inhibitors and SOCS mimetics as treatment options for autoimmune uveitis, psoriasis, lupus, and autoimmune encephalitis.
Pandey R; Bakay M; Hakonarson H
Front Immunol; 2023; 14():1271102. PubMed ID: 38022642
[TBL] [Abstract][Full Text] [Related]
43. JAK inhibitors in 2019, synthetic review in 10 points.
Muller R
Eur J Intern Med; 2019 Aug; 66():9-17. PubMed ID: 31178258
[TBL] [Abstract][Full Text] [Related]
44. Emerging Topical and Systemic JAK Inhibitors in Dermatology.
Solimani F; Meier K; Ghoreschi K
Front Immunol; 2019; 10():2847. PubMed ID: 31849996
[TBL] [Abstract][Full Text] [Related]
45. The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases.
Damsky W; Peterson D; Ramseier J; Al-Bawardy B; Chun H; Proctor D; Strand V; Flavell RA; King B
J Allergy Clin Immunol; 2021 Mar; 147(3):814-826. PubMed ID: 33129886
[TBL] [Abstract][Full Text] [Related]
46. Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis.
Iwata S; Tanaka Y
Expert Rev Clin Immunol; 2016 Oct; 12(10):1047-57. PubMed ID: 27253519
[TBL] [Abstract][Full Text] [Related]
47. Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthma.
Zak M; Dengler HS; Rajapaksa NS
Bioorg Med Chem Lett; 2019 Oct; 29(20):126658. PubMed ID: 31522830
[TBL] [Abstract][Full Text] [Related]
48. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis.
Harigai M
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i34-i42. PubMed ID: 30806708
[TBL] [Abstract][Full Text] [Related]
49. Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology.
Cinats A; Heck E; Robertson L
Skin Therapy Lett; 2018 May; 23(3):5-9. PubMed ID: 29772037
[TBL] [Abstract][Full Text] [Related]
50. Off-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Diseases.
Agarwal A; Diaz A; Al-Dehneem R; Pineda RM; Khattri S
J Drugs Dermatol; 2023 Dec; 22(12):1183-1190. PubMed ID: 38051858
[TBL] [Abstract][Full Text] [Related]
51. Upadacitinib (Rinvoq) - a new JAK inhibitor for rheumatoid arthritis.
Med Lett Drugs Ther; 2019 Nov; 61(1585):183-185. PubMed ID: 31770358
[No Abstract] [Full Text] [Related]
52. Curcumin and Curcuma longa Extract in the Treatment of 10 Types of Autoimmune Diseases: A Systematic Review and Meta-Analysis of 31 Randomized Controlled Trials.
Zeng L; Yang T; Yang K; Yu G; Li J; Xiang W; Chen H
Front Immunol; 2022; 13():896476. PubMed ID: 35979355
[TBL] [Abstract][Full Text] [Related]
53. Research trends of Janus Kinase inhibitors: a bibliometric and visualized study from 2012 to 2023.
Chang HC; Tsai RY; Lee CY; Kuan YH; Liao WC; Chen SJ; Gau SY
Eur Rev Med Pharmacol Sci; 2023 Dec; 27(24):12088-12102. PubMed ID: 38164871
[TBL] [Abstract][Full Text] [Related]
54. Emerging therapies for atopic dermatitis: JAK inhibitors.
Cotter DG; Schairer D; Eichenfield L
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S53-S62. PubMed ID: 29248518
[TBL] [Abstract][Full Text] [Related]
55. [JAK inhibitors in the management of rheumatoid arthritis].
Finckh A
Rev Med Suisse; 2019 Mar; 15(641):528-532. PubMed ID: 30860322
[TBL] [Abstract][Full Text] [Related]
56. Selective JAK inhibitors in development for rheumatoid arthritis.
Norman P
Expert Opin Investig Drugs; 2014 Aug; 23(8):1067-77. PubMed ID: 24818516
[TBL] [Abstract][Full Text] [Related]
57. The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.
Crowley EL; Fine SC; Katipunan KK; Gooderham MJ
J Cutan Med Surg; 2019; 23(3):289-297. PubMed ID: 30688081
[TBL] [Abstract][Full Text] [Related]
58. JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases.
Kahn J; Deverapalli SC; Rosmarin D
Semin Cutan Med Surg; 2018 Sep; 37(3):198-208. PubMed ID: 30215638
[TBL] [Abstract][Full Text] [Related]
59. A literature review on Janus kinase (JAK) inhibitors for the treatment of immunobullous disorders.
Kalantari Y; Sadeghi S; Asadi D; Goodarzi A
Int Immunopharmacol; 2022 Sep; 110():108923. PubMed ID: 35717838
[TBL] [Abstract][Full Text] [Related]
60. Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review.
Wen J; Hu H; Chen M; Yang H; Zhao Y; Liu Y
J Immunol Res; 2021; 2021():2324400. PubMed ID: 34966823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
